Merck KGaA (NYSE: MRK), Darmstadt, Germany, and Pfizer (NYSE: PFE) today announced the initiation of two Phase III studies of avelumab*, an investigational, fully human anti-PD-L1 IgG1 monoclonal antibody, in treating advanced or metastatic gastric/gastro-esophageal junction (GEJ) cancers, which are aggressive cancers with poor survival rates. These pivotal trials are investigating avelumab in the first-line and third-line settings, with overall survival (OS) as the primary endpoint in both trials.
http://www.streetinsider.com/Corporate+News/Merck+(MRK)+and+Pfizer+(PFE)+Initiate+Two+Phase+III+Studies+of+Avelumab+in+Advanced+GEJ+Cancers/11139944.html
Merck (MRK) and Pfizer (PFE) Initiate Two Phase III Studies of Avelumab in Advanced GEJ Cancers